Loftus, B <br/><br/>
Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies.  [electronic resource] 

 -  Clinical immunology (Orlando, Fla.)  May 2009 
 - 202-15 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1521-7035 
<br/><br/><label>Standard No.: </label>10.1016/j.clim.2009.01.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Dose-Response Relationship, Drug<br/>Humans<br/>Immunologic Factors--adverse effects<br/>Immunotherapy--standards<br/>Infusions, Subcutaneous<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Myelin Basic Protein--genetics<br/>T-Lymphocytes--immunology<br/>Treatment Outcome<br/>Vaccines<br/>Vaccines, Attenuated--therapeutic use<br/>Vaccines, Subunit--adverse effects